<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="27872">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02743871</url>
  </required_header>
  <id_info>
    <org_study_id>C0341001</org_study_id>
    <nct_id>NCT02743871</nct_id>
  </id_info>
  <brief_title>Study Of PF-06817024 In Healthy Subjects And In Patients With Chronic Rhinosinusitis With Nasal Polyps</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Third-Party Open, Placebo-Controlled, Dose Escalating Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Single And Multiple Intravenous And Subcutaneous Doses Of PF-06817024 In Healthy Subjects Who May Be Mildly Atopic And Of Single Doses Of PF-06817024 In Patients With Chronic Rhinosinusitis With Nasal Polyps</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate safety, tolerability, pharmacokinetics, and
      pharmacodynamics of PF-06817024 in healthy volunteers who may be mildly atopic and in
      participants with chronic rhinosinusitis with nasal polyps
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs)</measure>
    <time_frame>Baseline (Day 0) up to 211 days after last dose of study medication</time_frame>
    <description>Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Treatment-emergent are events between first dose of study drug and up to 211 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Relatedness to Drug PF-06817024 was assessed by the investigator (Yes/No).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>Baseline (Day 0) up to 211 days after last dose of study medication</time_frame>
    <description>All Cohorts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Normalized Maximum Observed Plasma Concentration (Cmax(dn))</measure>
    <time_frame>Baseline (Day 0) up to 211 days after last dose of study medication</time_frame>
    <description>All Cohorts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Concentration (Tmax)</measure>
    <time_frame>Baseline (Day 0) up to 211 days after last dose of study medication</time_frame>
    <description>All Cohorts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-Time Profile from Time Zero to Infinity (AUCinf)</measure>
    <time_frame>Baseline (Day 0) up to 211 days after last dose of study medication</time_frame>
    <description>Single Dose Cohorts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-Time Curve Within Dosing Interval (AUCtau)</measure>
    <time_frame>Baseline (Day 0) up to 211 days after last dose of study medication</time_frame>
    <description>All Cohorts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Normalized Area Under the Concentration-Time Curve Within Dosing Interval (AUCtau (dn))</measure>
    <time_frame>Baseline (Day 0) up to 211 days after last dose of study medication</time_frame>
    <description>All Cohorts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Concentration Over Dosing Interval (Cav)</measure>
    <time_frame>Baseline (Day 0) up to 211 days after last dose of study medication</time_frame>
    <description>All Cohorts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Half Life (t1/2)</measure>
    <time_frame>Baseline (Day 0) up to 211 days after last dose of study medication</time_frame>
    <description>Single Dose Cohorts, Last (Second) Dose of Multiple Dose Cohorts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Residence Time (MRT)</measure>
    <time_frame>Baseline (Day 0) up to 211 days after last dose of study medication</time_frame>
    <description>Single Dose Cohorts, Last (Second) Dose Multiple Dose Cohorts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution at Steady State (Vss)</measure>
    <time_frame>Baseline (Day 0) up to 211 days after last dose of study medication</time_frame>
    <description>IV Cohorts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL)</measure>
    <time_frame>Baseline (Day 0) up to 211 days after last dose of study medication</time_frame>
    <description>IV Cohorts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F)</measure>
    <time_frame>Baseline (Day 0) up to 211 days after last dose of study medication</time_frame>
    <description>SC Cohorts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance (CL/F)</measure>
    <time_frame>Baseline (Day 0) up to 211 days after last dose of study medication</time_frame>
    <description>SC Cohorts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Observed Plasma Trough Concentration (Cmin)</measure>
    <time_frame>Baseline (Day 0) up to 211 days after last dose of study medication</time_frame>
    <description>Last (Second) Dose IV Cohorts, Last (Second) Dose SC Cohort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed Accumulated Ratio for Maximum Observed Plasma Concentration (Rac(Cmax))</measure>
    <time_frame>Baseline (Day 0) up to 211 days after last dose of study medication</time_frame>
    <description>Last (Second) Dose IV Cohorts, Last (Second) Dose SC Cohort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed Accumulated Ratio for Area Under the Concentration-Time Curve Without Dosing Interval (Rac(AUCtau))</measure>
    <time_frame>Baseline (Day 0) up to 211 days after last dose of study medication</time_frame>
    <description>Last (Second) Dose IV Cohorts, Last (Second) Dose SC Cohort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Anti-Drug Antibody (ADA)</measure>
    <time_frame>Baseline (Day 0) up to 211 days after last dose of study medication</time_frame>
    <description>The percentage of participants with positive ADA and neutralizing antibodies will be summarized for each treatment arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-Time Profile from Time Zero to the Time of the Last Quantifiable Concentration (AUClast)</measure>
    <time_frame>Baseline (Day 0) up to 211 days after last dose of study medication</time_frame>
    <description>Single Dose Cohorts</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">115</enrollment>
  <condition>Healthy</condition>
  <condition>Chronic Rhinosinusitis With Nasal Polyps</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg of PF-06817024 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 mg of PF-06817024 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg of PF-06817024 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mg of PF-06817024 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1000 mg of PF-06817024 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2000 mg of PF-06817024 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 mg subcutaneous dose of PF-06817024 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mg of PF-06817024 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV dose to be determined of PF-06817024 or placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-06817024</intervention_name>
    <description>Subjects will be given one dose of PF-06817024 intravenously</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_label>Cohort 8</arm_group_label>
    <arm_group_label>Cohort 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo for PF-06817024</intervention_name>
    <description>Subjects will be given one dose of placebo for PF-06817024 intravenously</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_label>Cohort 8</arm_group_label>
    <arm_group_label>Cohort 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-06817024</intervention_name>
    <description>Subjects will be given one dose of PF-06817024 subcutaneously</description>
    <arm_group_label>Cohort 7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo for PF-06817024</intervention_name>
    <description>Subjects will be given one dose of placebo for PF-06817024 subcutaneously</description>
    <arm_group_label>Cohort 7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-06817024</intervention_name>
    <description>Subjects will be given two doses of PF-06817024 intravenously</description>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo for PF-06817024</intervention_name>
    <description>Subjects will be given two doses of PF-06817024 intravenously</description>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Healthy male subjects, healthy female subjects of non-childbearing potential, 18-55
             years of age (Part 1)

          -  Male subjects, female subjects of non-childbearing potential, female subjects of
             childbearing potential with documented bilateral tubal ligation (tubes tied) or
             bilateral salpingectomy (tubes removed), 18-65 years of age, and 2 of the following
             symptoms: nasal congestion/obstruction, nasal discharge, face pain/pressure,or
             reduction/loss of smell (Part 2)

        Exclusion Criteria:

          -  Clinically significant diseases (cardiac, psychiatric, autoimmune, renal, etc.),
             positive urine drug test, fever within 7 days of dosing, active infections within 28
             days of dosing (Part 1 and 2)

          -  History of allergic reaction to topical lidocaine, nasal surgery within 6 months
             (Part 2)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
  </overall_contact>
  <location>
    <facility>
      <name>New Haven Clinical Research Unit</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute, Inc.</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55402</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ear, Nose &amp; Throat Specialty Care of Minnesota, P.A.</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Prism Research, LLC</name>
      <address>
        <city>St. Paul</city>
        <state>Minnesota</state>
        <zip>55114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=C0341001&amp;StudyName=A+Phase+1%2C+Randomized%2C+Double-blind%2C+Third-party+Open%2C+Placebocontrolled%2C+Dose+Escalating+Study+To+Evaluate+The+Safety%2C+Tolerability%2C+Pharmacokinetics+And+Pharmacodynamics+Of+Single+And+Multiple+Intravenous+And+Subcutaneous+Doses+Of+Pf-06817024+In+Healthy+Subjects+Who+Are+Mildly+Atopic+And+Of+Single+Doses+Of+Pf-06817024+In+Patients+With+Chronic+Rhinosinusitis+With+Nasal+Polyps</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=C0341001&amp;StudyName=A+Phase+1%2C+Randomized%2C+Double-blind%2C+Third-party+Open%2C+Placebo-controlled%2C+Dose+Escalating+Study+To+Evaluate+The+Safety%2C+Tolerability%2C+Pharmacokinetics+And+Pharmacodynamics+Of+Single+And+Multiple+Intravenous+And+Subcutaneous+Doses+Of+Pf-06817024+In+Healthy+Subjects+Who+Are+Mildly+Atopic+And+Of+Single+Doses+Of+Pf-06817024+In+Patients+With+Chronic+Rhinosinusitis+With+Nasal+Polyps</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=C0341001&amp;StudyName=A+Phase+1%2C+Randomized%2C+Double-blind%2C+Third-party+Open%2C+Placebo-controlled%2C+Dose+Escalating+Study+To+Evaluate+The+Safety%2C+Tolerability%2C+Pharmacokinetics+And+Pharmacodynamics+Of+Single+And+Multiple+Intravenous+And+Subcutaneous+Doses+Of+Pf-06817024+In+Healthy+Subjects+Who+May+Be+Mildly+Atopic+And+Of+Single+Doses+Of+Pf-06817024+In+Patients+With+Chronic+Rhinosinusitis+With+Nasal+Polyps</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 27, 2017</lastchanged_date>
  <firstreceived_date>April 15, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FIH, Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Polyps</mesh_term>
    <mesh_term>Sinusitis</mesh_term>
    <mesh_term>Nasal Polyps</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
